Sai Life Sciences Ltd
Sai Life Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.
From Sai Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand.
- The company foresees 15% to 20% revenue CAGR over a three-year period, with some years possibly outperforming this range.
- New capacity expansions, including a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity), are planned to support growth.
- Current capacity utilization is around 60%, leaving headroom for near-term growth without immediate incremental capacity.
- Growth will be bolstered by both development and commercial contracts, with diversification across multiple molecules and modalities.
- Visibility from customer discussions indicates ongoing active engagements and pipeline progress feeding future capacity requirements.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.
- Starting expansion of a new mixed-use site in Hyderabad, expected to be operational within 18-24 months; will include non-GMP, peptide, and GMP capacities.
- Animal health Phase I expansion targeted for completion by March ’27, enabling validation and commercialization of veterinary API products; current investment less than INR 50 crores with an additional INR 70-75 crores planned for next phase.
- Ongoing R&D expansions:
- First phase at Hyderabad Unit 8 commissioning in Q4 FY’26 with ~200 fume hoods.
- New process facility R&D building commissioning by Sept ’26, doubling process R&D capacity.
- Peptide process development and pilot facility targeted for Sept ’26.
- OEB laboratories for ADC capabilities completion by Oct ’26.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Sai Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Sai Life Sciences Ltd Q3 FY26 results?
Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.